Efficacy and Safety of Apolipoprotein C‐ <scp>III</scp> Inhibitors in Hypertriglyceridemia: A Network Meta‐Analysis of Randomised Controlled Trials

ApoC-III inhibitors significantly improved triglyceride levels and other lipid parameters and, most importantly, substantially reduced the risk of acute pancreatitis. Future trials are needed to evaluate their effects on cardiovascular outcomes.